OncRef

Clinical Trial: NCT04401774

Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Memorial Sloan Kettering Cancer Center
Information Provided By:Memorial Sloan Kettering Cancer Center
Last Update Posted:2026-01-27

Study Overview

Brief Summary

The purpose of this additional part of the study is to test whether the study drug, nivolumab, is a safe treatment that will prevent participants' primary central nervous system lymphoma (PCNSL) from growing again (recurrence). Participants will be people with PCNSL who continue to have cell free tumor DNA (cfDNA) in their CSF despite completion of their first treatment (first-line treatment).

Official Title

Phase II Maintenance Trial of Nivolumab for Newly Diagnosed PCNSL Patients With Persistent Circulating Tumor DNA in the CSF After Completion of Methotrexate-Based First-Line Induction Chemotherapy

Conditions

Primary Central Nervous System Lymphoma (PCNSL)

Intervention / Treatment

  • Drug: Nivolumab

Other Study ID Numbers

  • 19-383

Start Date (Actual)

2020-05-22

Primary Completion Date (Actual)

2026-01-22

Study Completion Date (Actual)

2026-01-22

Enrollment (Actual)

14

Study Type

Interventional

Phase

Phase 2